Nephrology
IgAN
Expert Roundtables Podcast: Advances and Future Directions in IgA Nephropathy Research
Clinical research has led to the US Food and Drug Administration (FDA) approval of a handful of effective targeted therapies for IgA nephropathy (IgAN). Research on other agents is ongoing, and there is hope that clinical outcomes can be further improved with combination therapies. Our featured experts review recent and ongoing research and their potential impact on the future of IgAN.
Barratt J, Lafayette RA, Floege J. Therapy of IgA nephropathy: time for a paradigm change. Front Med (Lausanne). 2024;11:1461879. doi:10.3389/fmed.2024.1461879
Cheung CK, Alexander S, Reich HN, Selvaskandan H, Zhang H, Barratt J. The pathogenesis of IgA nephropathy and implications for treatment. Nat Rev Nephrol. 2024 Sep 4;10.1038/s41581-024-00885-3. doi:10.1038/s41581-024-00885-3
Hunter-Dickson M, Wong MG. The role of endothelin receptor antagonists in IgA nephropathy. Nephrology (Carlton). 2024;29(suppl 2):30-33. doi:10.1111/nep.14364
Lim RS, Yeo SC, Barratt J, Rizk DV. An update on current therapeutic options in IgA nephropathy. J Clin Med. 2024;13(4):947. doi:10.3390/jcm13040947
Selvaskandan H, Barratt J, Cheung CK. Novel treatment paradigms: primary IgA nephropathy. Kidney Int Rep. 2023;9(2):203-213. doi:10.1016/j.ekir.2023.11.026
Selvaskandan H, Jhaveri KD, Rizk DV. Primary IgA nephropathy: new insights and emerging therapies. Adv Kidney Dis Health. 2024;31(3):180-193. doi:10.1053/j.akdh.2024.04.002
Suzuki Y. B cell targeting in IgA nephropathy. Nephrology (Carlton). 2024;29(suppl 2):39-43. doi:10.1111/nep.14367
